Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
Programmable gene control platform for advanced cell therapies
Laverock Therapeutics is a biotechnology company developing a programmable gene control platform for the creation of disease-responsive advanced therapies. The platform uses recoded microRNAs to deliver tunable, stable and multiplexed gene silencing within cell therapies, enabling enhanced precision and improved…
Multivalent linker technologies for antibody-drug conjugate therapeutics
Spirea is a biopharmaceutical company developing antibody-drug conjugate technologies for targeted cancer treatment. Its multivalent linker platform is designed to attach a wider range of drug payloads to antibodies while enabling higher payload loading and controlled delivery. Spirea conducts preclinical research on…
Therapeutics to restore egg quality and improve IVF outcomes
U-Ploid Biotechnologies is an early-stage biotechnology company developing first-in-class therapeutics to address age-related decline in egg quality. Its lead programme targets chromosomal instability in human oocytes which is a primary driver of IVF failure, miscarriage, and congenital disorders in women of advanced…
Precision cancer vaccines to prevent metastatic recurrence
Infinitopes is a clinical-stage biotechnology company developing therapeutic cancer vaccines designed to prevent metastatic recurrence. Its lead candidate ITOP1 is a precision viral vector cancer vaccine targeting tumour antigens in patients with surgically resectable oesophageal adenocarcinoma, to be administered in…
Immunometabolism-targeting small molecules for autoimmune disease
Sitryx Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics that modulate immune cell metabolism to achieve disease remission in autoimmune and inflammatory conditions. The company's approach targets novel metabolic enzymes within immune cells, with lead programmes in…
TYK2/JAK1 inhibitor advancing towards Phase 2 psoriasis trials
Sareum is a clinical-stage biotechnology company developing small-molecule kinase inhibitors for autoimmune diseases and cancer. Its lead oral TYK2/JAK1 inhibitor, SDC-1801, completed Phase 1 testing in healthy volunteers and is being prepared for a Phase 2 study in psoriasis. Dosing in its Phase 2-enabling toxicology…
Infectious disease drug development and partnering organisation
Infex Therapeutics is a clinical-stage drug development company focused on antimicrobial resistance and pandemic-priority infectious diseases, based at Alderley Park. Founded as The AMR Centre in 2016, the company acquires and co-develops novel therapeutics through in-licensing and risk-sharing partnerships with…
Blue-mussel-derived bioactive peptide therapy for veterinary research
N2 Pharmaceuticals develops N2-01, an injectable mixture of bioactive peptides and amino acids derived from blue mussels. Its research focuses on endothelial dysfunction and vascular permeability, with potential applications in veterinary medicine and human disease. The company reports historic veterinary use in…
Bacterial-like particle vaccine platform targeting recurrent UTIs
Spectre Bio is a biotechnology company developing a non-antibiotic prophylactic vaccine for recurrent UTIs, a major unmet medical need and significant driver of antimicrobial resistance. The company's platform produces programmable, non-replicative bacterial cells that retain a full native antigen profile while being…
Oral NLRP3 inhibitors for cardiovascular and neurologic inflammation
Rezera, formerly NodThera, is a clinical-stage biotechnology company developing small molecule inhibitors of NLRP3, an inflammasome implicated in chronic inflammatory and neurodegenerative disease. Its lead asset, ruvonoflast, is a brain-penetrant oral inhibitor that has completed Phase II trials and is advancing…
Synthetic psilocybin therapy for treatment-resistant depression and PTSD
Compass Pathways is a clinical-stage biopharmaceutical company developing synthetic psilocybin-based treatments for mental health conditions. Its lead candidate, COMP360, is a proprietary synthesised psilocybin formulation administered alongside structured psychological support. COMP360 holds FDA Breakthrough Therapy…
Monoclonal antibodies for viral infectious disease
RQ Biotechnology is a passive immunisation company discovering and developing long-acting monoclonal antibodies to provide immediate protection against viral infections in immunocompromised and vulnerable populations. Founded by members of the UK COVID-19 Antibody Taskforce and co-founded with LifeArc, the company's…
Tissue-targeted gene and RNA delivery platforms for rare and neurological disease
Dawn Therapeutics is a pre-clinical biotechnology company developing precision delivery platforms for genetic medicines targeting the central nervous system, cartilage, and bone. Its transferrin receptor-guided system is designed to cross the blood-brain barrier and deliver RNA or DNA payloads to neuronal tissues,…
Topical peptide therapeutics targeting inflammatory skin disease
Carocell Bio is a pre-clinical stage biotechnology company developing proprietary peptide-based therapeutics for inflammatory diseases. Its pipeline centres on topical formulations that inhibit mitogen-activated protein kinase (MAPK/p38), a key regulator of the inflammatory cascade. Lead programmes target atopic…
Off-the-shelf Natural Killer cell therapies for solid and blood cancers
NK:IO develops cancer immunotherapies based on human Natural Killer cells, harnessing the body's innate immune system as an alternative to T-cell-based approaches. The company's patented platform activates cord blood-derived stem cells to produce NK cells at high potency and yield, addressing manufacturing challenges…
Virus-like particle vaccine platform for infectious disease and diagnostics
iQur is a London-based biotechnology company developing vaccines using its proprietary tandem core virus-like particle platform. The technology uses the hepatitis B virus core protein to display multiple antigens simultaneously, stimulating strong immune responses without the risks of live or attenuated viruses.…
Oligonucleotide therapeutics designed to upregulate protein expression
Orfonyx Bio is a biotechnology company developing genetic medicines that increase, rather than silence, the expression of therapeutic target proteins. Its platform generates antisense oligonucleotide modulators that act on regulatory elements within the untranslated regions of genes, inhibiting sequence motifs that…
Novel small-molecule anti-fibrinolytic for acute traumatic and surgical bleeding
ClotProtect Therapeutics is a University of Leeds spin-out developing a first-in-class small molecule anti-fibrinolytic to address acute bleeding following trauma and surgery. The company's approach directly inhibits the enzyme responsible for blood clot breakdown, aiming to offer greater efficacy than current…
Oncolytic adenovirus therapeutics for solid tumour cancer treatment
PsiVac is a UK-based biotechnology company developing oncolytic virus therapeutics for the treatment of cancer. Its patented technology uses genetically modified adenoviruses engineered to selectively replicate within and destroy tumour cells while leaving healthy cells intact, while also stimulating the body's immune…
Exosome-delivered gene editing therapies for neurodegenerative diseases
Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies for rare, genetically driven neurodegenerative diseases. Its proprietary platform uses engineered exosomes to deliver CRISPR-based gene editors across the blood-brain barrier, enabling targeted genetic intervention in the…